Long LLY on retatrutide triple-agonist clinical data showing weight, A1C, sleep apnea, and osteoarthritis improvements presented at ADA

This is a Tier A hard catalyst — official clinical data released by Lilly at a major medical conference (ADA), corroborated by the company's own investor relations page. Retatrutide's multi-indication efficacy data expands the addressable market well beyond GLP-1 peers. The market is likely to reprice LLY's pipeline value upward in the days following the ADA presentation, especially with healthcare (XLV) already leading sector performance this week.

Retatrutide is still in trials and not yet approved; if the full data package reveals safety signals (e.g., elevated heart rate, GI tolerability issues at higher doses) in the detailed ADA presentation, the initial enthusiasm could reverse sharply.